본문 바로가기
KERD
논문KCI 등재

Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation

Jong Man Kim|Jongwook Oh
대한간학회 (The korean Association for the Study of the Liver)|2020.01|Clinical and Molecular Hepatology|제26권 제1호|pp. 1-6

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

ComplicationsRejectionImmunosuppressionGraft survival

초록

Antibody mediated rejection (AMR) after adult ABO-incompatible living donor liver transplantation (ABO-I LDLT) induced hepatic necrosis or diffuse intrahepatic biliary complications, which were related with poor graft and patient survival. Various desensitization protocols have been used to overcome these problems. Since using rituximab, the outcomes of ABO-I LDLT show a similar survival rate to those of ABO-compatible living donor liver transplantation. However, diffuse bile duct complications still occur after ABO-I LDLT. We have reviewed the past and current immune strategies for desensitization and to provide outcomes and ABO incompatibility-related complications in ABO-I LDLT.

Abstract

Antibody mediated rejection (AMR) after adult ABO-incompatible living donor liver transplantation (ABO-I LDLT) induced hepatic necrosis or diffuse intrahepatic biliary complications, which were related with poor graft and patient survival. Various desensitization protocols have been used to overcome these problems. Since using rituximab, the outcomes of ABO-I LDLT show a similar survival rate to those of ABO-compatible living donor liver transplantation. However, diffuse bile duct complications still occur after ABO-I LDLT. We have reviewed the past and current immune strategies for desensitization and to provide outcomes and ABO incompatibility-related complications in ABO-I LDLT.

참고문헌 (36)

  1. Demetris AJ, "Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers", Am J Pathol, 132, pp.489~502 (1988)
  2. Gugenheim J, "Liver transplantation across ABO blood group barriers", Lancet, 336, pp.519~523 (1990)
  3. Farges O, "The use of ABO-incompatible grafts in liver transplantation : a life-saving procedure in highly selected patients", Transplantation, 59, pp.1124~1133 (1995)
  4. Lo CM, "Risk factors for liver transplantation across the ABO barrier", Transplantation, 58, pp.543~547 (1994)
  5. Kawagishi N, "ABO-incompatible living donor liver transplantation : new insights into clinical relevance", Transplantation, 85, pp.1523~1525 (2008)
  6. Egawa H, "Impact of recipient age on outcome of ABO-incompatible livingdonor liver transplantation", Transplantation, 77, pp.403~411 (2004)
  7. Ikegami T, "Rituximab, IVIG, and plasma exchange without graft local infusion treatment : a new protocol in ABO incompatible living donor liver transplantation", Transplantation, 88, pp.303~307 (2009)
  8. Egawa H, "Present status of ABO-incompatible living donor liver transplantation in Japan", Hepatology, 47, pp.143~152 (2008)
  9. Raut V, "Management of ABO-incompatible livingdonor liver transplantation : past and present trends", Surg Today, 41, pp.317~322 (2011)
  10. Kim JM, "ABOincompatible living donor liver transplantation is suitable in patients without ABO-matched donor", J Hepatol, 59, pp.1215~1222 (2013)
  11. Song GW, "Biliary stricture is the only concern in ABO-incompatible adult living donor liver transplantation in the rituximab era", J Hepatol, 61, pp.575~582 (2014)
  12. Kim JM, "Casematched comparison of ABO-incompatible and ABO-compatible living donor liver transplantation", Br J Surg, 103, pp.276~283 (2016)
  13. Song GW, "ABOincompatible adult living donor liver transplantation under the desensitization protocol with rituximab", Am J Transplant, 16, pp.157~170 (2016)
  14. Yamamoto H, "Feasibility of monotherapy by rituximab without additional desensitization in ABO-incompatible living-donor liver transplantation", Transplantation, 102, pp.97~104 (2018)
  15. Kim SH, "A simplified protocol using rituximab and immunoglobulin for ABO-incompatible low-titre living donor liver transplantation", Liver Int, 38, pp.932~939 (2018)
  16. Lee EC, "A comparison of desensitization methods : rituximab with", without plasmapheresis in ABO-incompatible living donor liver transplantation, 2018, pp.17, 119~125
  17. Kim JD, "Single-center experience of ABOincompatible living-donor liver transplantation with a new simplified intravenous immunoglobulin protocol : a propensity score-matching analysis", Transplant Proc, 48, pp.1134~1138 (2016)
  18. Lee J, "Results of ABOincompatible liver transplantation using a simplified protocol at a single institution", Transplant Proc, 47, pp.723~726 (2015)
  19. Lee SD, "ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy", HPB(Oxford), 16, pp.807~813 (2014)
  20. Raut V, "Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab", Transplantation, 93, pp.99~105 (2012)
  21. Starzl TE, "Fifteen years of clinical liver transplantation", Gastroenterology, 77, pp.375~388 (1979)
  22. Sanchez-Urdazpal L, "Increased bile duct complications in ABO incompatible liver transplant recipients", Transplant Proc, 23(1 Pt 2), pp.1440~1441 (1991)
  23. Kozaki K, "The role of apheresis therapy for ABO incompatible living donor liver transplantation : the Kyoto University experience", Ther Apher Dial, 10, pp.441~448 (2006)
  24. Egawa H, "Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation : a Japanese multicenter study", Am J Transplant, 14, pp.102~114 (2014)
  25. Tanabe M, "Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation", Transplantation, 73, pp.1959~1961 (2002)
  26. Tanabe M, "Current progress in ABO-incompatible liver transplantation", Eur J Clin Invest, 40, pp.943~949 (2010)
  27. Takaya S, "Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1", Transplantation, 54, pp.927~929 (1992)
  28. Kozaki K, "Therapeutic strategy and the role of apheresis therapy for ABO incompatible living donor liver transplantation", Ther Apher Dial, 9, pp.285~291 (2005)
  29. Egawa H, "B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation", Liver Transpl, 13, pp.579~588 (2007)
  30. Uchiyama H, "Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange", Transplantation, 92, pp.1134~1139 (2011)
  31. Genberg H, "Pharmacodynamics of rituximab in kidney allotransplantation", Am J Transplant, 6, pp.2418~2428 (2006)
  32. Skogsberg U, "Adult ABO-incompatible liver transplantation, using A and B donors", Xenotransplantation, 13, pp.154~159 (2006)
  33. Kim JM, "ABOincompatible living donor liver transplantation with rituximab and total plasma exchange does not increase hepatocellular carcinoma recurrence", Transplantation, 102, pp.1695~1701 (2018)
  34. Yoon YI, "Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma", J Hepatol, 68, pp.1153~1162 (2018)
  35. Pratschke J, "Promising recent data on ABO incompatible liver transplantation : restrictions may apply", Transpl Int, 20, pp.647~648 (2007)
  36. Toso C, "ABO-incompatible liver transplantation for critically ill adult patients", Transpl Int, 20, pp.675~681 (2007)

관련 논문AI추천

Liver TransplantationDeok-Bog Moon, Sung-Gyu Lee거트앤리버 소화기연관학회협의회 · Gut and Liver2009 · 제3권 제3호Outcome of donor biliary complications following living donor liver transplantationDong Goo Kim, Ho Jong Chun, Hyun Young Woo, In Seok Lee, Jae Hyuck Chang, Jong Young Choi, Seung Bae Youn, Seung Kew Yoon, Si Hyun Bae, Young Kyoung You대한내과학회 · The Korean Journal of Internal Medicine2018 · 제33권 제4호Biliary Complications after Living Donor Liver Transplantation Differ from Those after Deceased Donor Liver TransplantationJang Sung Ill, Lee Dong Ki거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제2호Liver graft from donation after circulatory death donor: Real practice to improve graft viabilityKoji Hashimoto대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제4호Usefulness of the Rendezvous Technique for Biliary Stricture after Adult Right-Lobe Living-Donor Liver Transplantation with Duct-To-Duct Anastomosis김동구, 유영경, 윤승규, 이인석, 정인식, 정재혁, 천호종, 최규용, 최명규, 최종영거트앤리버 소화기연관학회협의회 · Gut and Liver2010 · 제4권 제1호A Case of Bidirectional ABO- and RhD-Incompatible Liver Transplantation in a Mongolian Patient With Asian-Type DELCho Duck, Choi Ryoojung, Kang Takho, Kim Dae Won, Kim Dong-Sik대한진단검사의학회 · Annals of Laboratory Medicine2025 · 제45권 제1호

이 간행물의 다른 논문 (10건)

The fibrogenic process and the unleashing of acute-on-chronic liver failureMisael Uribe, Mayra Dóminguez-Pérez, Guillermo Nahúm López-Sánchez, Natalia Nuño-Lámbarripp. 7-15Extrahepatic manifestations of hepatitis E virus: An overviewIoannis V. Mitselos, Fotios S. Fousekis, Dimitrios K. Christodouloupp. 16-23A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in KoreaKwang-Hyub Han, Jae Seung Lee, Doyoung Kim, Jin Sil Seong, Jun Yong Park, Seung Up Kim, Beom Kyung Kim, Sang Hoon Ahnpp. 24-32Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection한광협, 안상훈, 김범경, 박준용, 김도영, Young Nyun Park, 김승업, Hye Soo Kim, Dai Hoon Han, Kyung Sik Kim, Jin Sub Choi, 최기홍, 김현숙pp. 33-44Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell lineAnuradha Chakraborti, Ramanpreet Kaur, Shruthi Kanthaje, Sakshi Sharma, Harpreet Kaur, Ankita Makolpp. 45-53
원문 보기